Q3 Earnings Estimate for Pharvaris Issued By Leerink Partnrs

Key Points

• Leerink Partners has revised its Q3 2025 earnings forecast for Pharvaris to a loss of ($0.77) per share, up from a prior estimate of ($0.89).
• Despite missing previous earnings estimates, Pharvaris has a consensus rating of "Buy" among five analysts, with an average price target of $35.60.
• Pharvaris is currently valued at $1.17 billion and has experienced significant volatility, with a fifty-two week range between $11.51 and $26.33.

Pharvaris N.V. (NASDAQ:PHVS - Free Report) - Equities research analysts at Leerink Partnrs lifted their Q3 2025 EPS estimates for Pharvaris in a research note issued to investors on Wednesday, August 13th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings of ($0.77) per share for the quarter, up from their prior estimate of ($0.89). The consensus estimate for Pharvaris' current full-year earnings is ($2.71) per share. Leerink Partnrs also issued estimates for Pharvaris' Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($3.64) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.81) EPS, Q3 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($0.84) EPS, FY2026 earnings at ($3.27) EPS and FY2027 earnings at ($2.14) EPS.

Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.94) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.07).

A number of other research firms have also weighed in on PHVS. JMP Securities lowered their price target on shares of Pharvaris from $55.00 to $52.00 and set a "market outperform" rating on the stock in a research report on Wednesday, August 13th. Wedbush restated an "outperform" rating and set a $27.00 price target on shares of Pharvaris in a research report on Thursday, June 5th. Zacks Research upgraded shares of Pharvaris from a "strong sell" rating to a "hold" rating in a research report on Monday. Guggenheim initiated coverage on shares of Pharvaris in a report on Wednesday, June 11th. They issued a "buy" rating and a $32.00 target price on the stock. Finally, Cantor Fitzgerald decreased their target price on shares of Pharvaris from $28.00 to $25.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $35.60.

Pharvaris Price Performance

PHVS traded down $0.23 on Monday, reaching $23.12. 53,502 shares of the company's stock were exchanged, compared to its average volume of 142,735. The stock has a market cap of $1.21 billion, a PE ratio of -6.88 and a beta of -2.81. Pharvaris has a twelve month low of $11.51 and a twelve month high of $26.33. The stock's fifty day moving average price is $20.27 and its 200-day moving average price is $17.43.

Institutional Investors Weigh In On Pharvaris

Institutional investors and hedge funds have recently made changes to their positions in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Pharvaris by 30.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,734 shares of the company's stock valued at $1,222,000 after acquiring an additional 14,838 shares during the period. Deutsche Bank AG raised its stake in shares of Pharvaris by 13.0% in the 4th quarter. Deutsche Bank AG now owns 18,168 shares of the company's stock valued at $348,000 after acquiring an additional 2,087 shares during the period. Bank of America Corp DE raised its stake in shares of Pharvaris by 205,286.7% in the 4th quarter. Bank of America Corp DE now owns 30,808 shares of the company's stock valued at $591,000 after acquiring an additional 30,793 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Pharvaris by 1,125.3% in the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after acquiring an additional 2,847 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Pharvaris in the 4th quarter valued at approximately $64,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.